Business Context and Reporting Period
This Form 6-K filing by Newcelx Ltd. (NewcelX) covers the month of November 2025. The report announces a significant executive leadership change following the closing of the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel appointments rather than financial performance data.
Material Changes
- Executive Appointment: Mr. Omri Hagai has been appointed as Chief Financial Officer (CFO), effective December 10, 2025.
- Executive Departure: Mr. Uri Ben Or, the Interim CFO, will step down effective December 10, 2025.
- Reason for Change: The departure of Mr. Ben Or is not due to any disagreement with the Company or matters related to its operations, policies, or practices.
Management Commentary and Background
Management highlights Mr. Hagai's extensive experience in public companies within the technology and industrial sectors. His background includes roles at Israel Chemicals Ltd. (2016–2021), Director of Finance at BrainsWay Ltd. (2021–2023), and CFO at Saverone 2014 Ltd. (2023–present). He holds a bachelor's degree in Business Management and Accounting from the Hebrew University of Jerusalem and is a Certified Public Accountant in Israel.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (December 10, 2025).
- Verify the completion status of the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd.
- Review Mr. Hagai's prior disclosures and performance at Saverone 2014 Ltd. and BrainsWay Ltd.
- Check for any subsequent filings regarding the Interim CFO's departure or new compensation arrangements.